References
- Andersen K. W., Mouridsen H. T., Castberg T., et al. Organization of the Danish adjuvant trials in breast cancer. Dan. Med. Bull. 1981; 28: 102
- Bartolucci A. A. Estimations and comparisons of proportions. Cancer clinical trials—Methods and practice, M. E Buyse, M. J Staquet, R. J. Sylvester. (EORTC). Oxford University Press, Oxford 1984; 337
- Beahrs O. H. Staging of cancer of the breast as a guide to therapy. Cancer 1984; 53: 592
- Bonadonna G., Rossi A., Valagussa P., Banfi A., Veronesi U. The CMF program for operable breast cancer with positive axillary nodes. Cancer 1977; 39: 2904
- Bross I. D. J. Is there an increased risk?. Fed. Proc. 1954; II: 815
- Cady B. Total mastectomy and partical axillary dissection. Surg. Clin. North Am. 1973; 53: 313
- Executive Committee of the Danish Breast Cancer Cooperative Group. Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. Lancet 1980; II: 824
- Fidler I. J., Kripke M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977; 197: 893
- Kamby C., Dirksen H., Vejborg I., et al. Incidence and methodologic aspects of the occurrence of liver metastases in recurrent breast cancer. Cancer 1987; 59: 1524
- Kamby C., Ejlertsen B., Andersen J., et al. Stage and pattern of metastases in patients with breast cancer. Eur. J. Cancer Clin. Oncol. 1987; 23: 1925
- Kamby C., Rose C. Metastatic pattern and response to endocrine therapy in human breast cancer. Breast Cancer Res. Treat. 1987; 8: 197
- Ludwig Breast Cancer Study Group. Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastatis. Lancet 1984; I: 1265
- Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in menopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res. 1985; 45: 4454
- Mouridsen H. T., Rose C., Brincker H., et al. Adjuvant systemic therapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res. 1984; 96: 117
- Patanaphan V., Salazar O. M., Poussin-Rosillo H. Prognosticators in recurrent breast cancer. Cancer 1984; 54: 228
- Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 1977; 35: 1
- Rose C., Mouridsen H. T., Thorpe S. M., Andersen J., Blichert-Toft M., Andersen K. W., The Danish Breast Cancer Cooperative Group. Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence. 72 months of life-table analysis and steroid hormone receptor status. World J. Surg. 1985; 9: 765
- Vincent M. D., Powles T. J., Skeet R., et al. An analysis of possible prognostic features of long-term and short-term survivors of metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 1986; 22: 1059